Atrial Fibrillation in a Patient with Hemophilia A: A Case Report and Therapeutic Challenges

The increasing age of patients with congenital hemophilia poses new challenges for clinicians. Not only the consequences of bleeding but also age-related diseases, especially cardiovascular disorders, are of great concern. Factors such as hypertension, diabetes, or hyperlipidemia further increase the cardiovascular risk in elderly patients with hemophilia. Preventive treatment of these cardiovascular diseases may therefore also be necessary in hemophilia patients. However, determining the optimal level of anticoagulation in patients with reduced levels of coagulation factors is often difficult and requires an individualized approach. Given the absence of substantial evidence from large clinical trials, clinicians rely on case reports and expert opinions to guide the therapy. This case report details the individual risk-benefit assessment and management of a 57-year-old hemophilia A patient with atrial fibrillation.

Authors

Institutions

Publication Details

Journal
Hämostaseologie
Published
2025-05-06
DOI
https://doi.org/10.1055/a-2496-1491
Primary Topic
Hemophilia Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Atrial Fibrillation in a Patient with Hemophilia A: A Case Report and Therapeutic Challenges

Günalp Uzun, Karina Althaus, Tamam Bakchoul, Stefanie Hammer et al.
Hämostaseologie
Hemophilia Treatment and Research
article

Atrial Fibrillation in a Patient with Hemophilia A: A Case Report and Therapeutic Challenges

Günalp Uzun, Karina Althaus, Tamam Bakchoul, Stefanie Hammer, Jürgen Schreieck
article en

Abstract

The increasing age of patients with congenital hemophilia poses new challenges for clinicians. Not only the consequences of bleeding but also age-related diseases, especially cardiovascular disorders, are of great concern. Factors such as hypertension, diabetes, or hyperlipidemia further increase the cardiovascular risk in elderly patients with hemophilia. Preventive treatment of these cardiovascular diseases may therefore also be necessary in hemophilia patients. However, determining the optimal level of anticoagulation in patients with reduced levels of coagulation factors is often difficult and requires an individualized approach. Given the absence of substantial evidence from large clinical trials, clinicians rely on case reports and expert opinions to guide the therapy. This case report details the individual risk-benefit assessment and management of a 57-year-old hemophilia A patient with atrial fibrillation.

Hämostaseologie
University Children's Hospital Tübingen (DE)
Bristol-Myers Squibb, CSL Behring, Deutsche Forschungsgemeinschaft, Novo Nordisk, Deutsche Herzstiftung, Swedish Orphan Biovitrum, Mitsubishi Tanabe Pharma Corporation, LEO Pharma, Bayer Vital, Novo Nordisk Pharma
Good health and well-being
Openalex Percentile: Top 88%
Hemophilia Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.